A Life Science Company

Health Canada approves VITRAKVI® (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion

Read more

Yellow Wood Partners to acquire iconic Dr. Scholl’s™ brand from Bayer

Yellow Wood Partners and Bayer announced today that Yellow Wood Partners has entered into a definitive agreement to buy the Dr. Scholl’s™ business from Bayer for a purchase price of 585 million U.S. dollars. Read more

Beiersdorf to acquire iconic Coppertone™ brand from Bayer

Divestiture enables Bayer to focus on core OTC business Read more

Bayer to sell its Animal Health business unit to Elanco for 7.6 billion U.S. dollars

Read more